BioSyent Pharma Launches New Urgent Care Product
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 11/14/16 -- BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has launched a new urgent care product, phenylephrine hydrochloride injection in the Aguettant System® pre-filled syringe ("Phenylephrine PFS"), for use in hospitals and acute care settings. The Company has already received two purchasing organization listings which give it access to more than 800 hospitals in Canada. In response to customer orders, shipments of the product have commenced.
As previously announced by BioSyent, the Phenylephrine PFS was approved by Health Canada on May 4, 2016. This product is indicated for the treatment of clinically important hypotensive states, including overcoming peripheral vascular failure (shock, or shock-like states), maintenance of blood pressure in the setting of anesthesia, drug-induced hypotension, or hypersensitivity with circulatory compromise.
The Aguettant System® for PFS offers a patented innovation that can be used for a variety of injectable medications. The Pharmapack award winning ready-to-use Aguettant System® for PFS features a needle-free, glass-free, sterile plastic syringe with a dual tamper-evident seal. In addition to atropine sulfate injection, phenylephrine hydrochloride injection is BioSyent's second urgent care product using the patented Aguettant System® and expands the product offerings of BioSyent's Hospital Business in Canada.
"Phenylephrine PFS more than doubles the revenue potential of our Aguettant System® sales in Canada," remarked Rene Goehrum, President and CEO of BioSyent, "and attracts no incremental sales and marketing expenses."
The Aguettant System® is licensed to BioSyent by Laboratoire Aguettant of Lyon, France for exclusive marketing and distribution in Canada. Aguettant has a more than 100 year history of providing innovative and patented infusion delivery systems to hospitals. The Aguettant System® for PFS has been available since 2009 and with more than 5 million units manufactured to date, it is used throughout Europe as well as the Middle East.
To learn more about the Aguettant System®, please visit the product website .
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.
As of the date of this press release, the Company has 14,101,087 shares issued and outstanding.
For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit .
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Contacts:
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.11.2016 - 13:00 Uhr
Sprache: Deutsch
News-ID 506673
Anzahl Zeichen: 0
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Alternative
Diese Pressemitteilung wurde bisher 251 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioSyent Pharma Launches New Urgent Care Product"
steht unter der journalistisch-redaktionellen Verantwortung von
BioSyent Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
